Literature DB >> 21748532

A comparative study of the usefulness of color vision, photostress recovery time, and visual evoked potential tests in early detection of ocular toxicity from hydroxychloroquine.

Javad Heravian1, Massoud Saghafi, Naser Shoeibi, Samira Hassanzadeh, Mohammad Taghi Shakeri, Maria Sharepoor.   

Abstract

Ocular toxicity from hydroxychloroquine (HCQ) is rare, but its potential permanence and severity makes it imperative to employ measures and screening protocols to minimize its occurrence. This study was performed to assess the usefulness of color vision, photo stress recovery time (PSRT), and visual evoked potentials (VEP) in early detection of ocular toxicity of HCQ, in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). 86 patients were included in the study and divided into three groups: (1) with history of HCQ use: interventional 1 (Int.1) without fundoscopic changes and Int.2 with fundoscopic changes; and (2) without history of HCQ use, as control. Visual field, color vision, PSRT and VEP results were recorded for all patients and the effect of age, disease duration, treatment duration and cumulative dose of HCQ on each test was assessed in each group. There was a significant relationship among PSRT and age, treatment duration, cumulative dose of HCQ and disease duration (P<0.001 for all). Color vision was normal in all the cases. P100 amplitude was not different between the three groups (P=0.846), but P100 latency was significantly different (P=0.025) and for Int.2 it was greater than the others. The percentage of abnormal visual fields for Int.2 was more than Int.1 and control groups (P=0.002 and P=0.005 respectively), but Int.1 and control groups were not significantly different (P>0.50). In the early stages of maculopathy, P100 latencies of VEP and PSRT are useful predictors of HCQ ocular toxicity. In patients without ocular symptoms and fundoscopic changes, the P100 latency of VEP predicts more precisely than the others.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21748532     DOI: 10.1007/s10792-011-9456-6

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  19 in total

1.  Sources of variability in the clinical photostress test.

Authors:  Tom H Margrain; David Thomson
Journal:  Ophthalmic Physiol Opt       Date:  2002-01       Impact factor: 3.117

2.  Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology.

Authors:  Michael F Marmor; Ronald E Carr; Michael Easterbrook; Ayad A Farjo; William F Mieler
Journal:  Ophthalmology       Date:  2002-07       Impact factor: 12.079

3.  Visual evoked potentials standard (2004).

Authors:  J Vernon Odom; Michael Bach; Colin Barber; Mitchell Brigell; Michael F Marmor; Alma Patrizia Tormene; Graham E Holder
Journal:  Doc Ophthalmol       Date:  2004-03       Impact factor: 2.379

4.  Blue-yellow perimetry can be an early detector of hydroxychloroquine and chloroquine retinopathy.

Authors:  Mohammad Reza Razeghinejad; Fatemeh Torkaman; Heydar Amini
Journal:  Med Hypotheses       Date:  2005       Impact factor: 1.538

5.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

6.  Management of patients undergoing hydroxychloroquine (Plaquenil) therapy.

Authors:  Harrison S Weisinger; Konrad Pesudovs; H Barry Collin
Journal:  Clin Exp Optom       Date:  2000 Jan-Feb       Impact factor: 2.742

Review 7.  Ocular toxicity of hydroxychloroquine.

Authors:  J C S Yam; A K H Kwok
Journal:  Hong Kong Med J       Date:  2006-08       Impact factor: 2.227

8.  Detection of color vision defects in chloroquine retinopathy.

Authors:  B L Vu; M Easterbrook; J K Hovis
Journal:  Ophthalmology       Date:  1999-09       Impact factor: 12.079

9.  Multifocal electroretinographic evaluation of long-term hydroxychloroquine users.

Authors:  Raj K Maturi; Minzhong Yu; Richard G Weleber
Journal:  Arch Ophthalmol       Date:  2004-07

10.  Ocular effects and safety of antimalarial agents.

Authors:  M Easterbrook
Journal:  Am J Med       Date:  1988-10-14       Impact factor: 4.965

View more
  1 in total

1.  Assessment of hydroxychloroquine maculopathy after cessation of treatment: an optical coherence tomography and multifocal electroretinography study.

Authors:  Marilita M Moschos; Eirini Nitoda; Irini P Chatziralli; Zisis Gatzioufas; Chryssanthi Koutsandrea; George Kitsos
Journal:  Drug Des Devel Ther       Date:  2015-06-11       Impact factor: 4.162

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.